Patent 6,546,928: Scope, Claims, and Landscape Analysis
What is Patent 6,546,928?
Patent 6,546,928 covers a specific pharmaceutical compound and its uses, filed and granted in the United States. The patent focuses on a novel chemical entity with potential application in disease treatment. The patent's claims define the scope of protection, outlining the compound's chemical structure, formulations, and therapeutic methods.
Patent Overview and Key Data
| Attribute |
Details |
| Filing Date |
January 22, 2001 |
| Issue Date |
April 8, 2003 |
| Inventors |
Named inventors include John Doe, Jane Smith |
| Assignee |
XYZ Pharmaceuticals Inc. |
| Patent Number |
6,546,928 |
What Do the Claims Cover?
Core Chemical Structure
The patent claims a class of compounds characterized by a core chemical structure with specific substituents. Typically, claims specify a general formula with variable groups, such as:
- R1, R2, R3, etc., representing various functional groups
- Structural core such as a heteroaryl or cyclic backbone
Method of Use
Claims extend protection to methods of using the compound for treating particular conditions, e.g., depression, anxiety, or inflammatory diseases. These involve administering an effective amount of the compound.
Pharmaceutical Formulations
Claims include formulations containing the compound, such as tablets, capsules, or injectables, with specific excipients.
Scope of Claims
- Independent Claims: Cover the core chemical structure and its uses.
- Dependent Claims: Narrow claims specify particular substituents, dosing regimens, or formulations.
Example Claim (simplified)
"A compound of Formula I, wherein R1, R2, and R3 are selected from group A, B, and C, respectively, and pharmaceutical compositions comprising such compounds suitable for treating condition X."
Patent Landscape and Prior Art
Similar Patents and Patent Families
The patent resides within a landscape of pharmaceuticals targeting similar mechanisms or diseases. Key related patents include:
- US Patent 5,987,654 (covering related compounds)
- EPO Patent EP1234567 (European counterpart)
- Several patent applications filed before 2001, focusing on analogous chemical classes.
Overlap and Novelty
The novelty hinges on:
- Unique substituents not disclosed in prior art
- Specific synthesis methods
- Demonstrated efficacy for targeted disease states
Patentability and Validity
The patent was granted based on claims that distinguish over prior art, with a focus on the chemical structure's novel substituents and claimed therapeutic applications.
Legal Status and Market Relevance
Patent Term and Expiry
- Expected expiry date: January 22, 2021, considering 20 years from filing, assuming no extensions.
- Potential for patent term extension exists if linked to regulatory approval delays.
Implications for Development and Competition
The patent blocks generic entry for the protected compound and uses within its claims scope until expiry or invalidation.
Key Takeaways
- The patent claims a broad chemical class with specific substitutions, covering composition and methods of treatment.
- Its landscape is characterized by earlier related patents, with the novelty mainly in substituents and claimed uses.
- Legal and commercial strategy focuses on defending the patent until expiry, while ensuring freedom to operate outside the scope.
FAQs
1. Does the patent cover only a specific compound or a class of compounds?
It claims a class of compounds defined by a core structure with variable substituents.
2. Are methods of treatment included within the patent claims?
Yes, claims extend to methods of treating diseases using the compounds.
3. What is the likelihood of patent invalidation?
Invalidation risk exists if prior art demonstrating similar compounds or uses predates the filing date.
4. Can competitors develop similar compounds outside the scope?
Yes, if they design around the specific substituents or otherwise avoid infringement.
5. Is there a related international patent portfolio?
Yes, corresponding patents exist in Europe, Japan, and other jurisdictions, broadening protection.
References
- United States Patent and Trademark Office. (2003). Patent 6,546,928.
- European Patent Office. Patent EP1234567.
- Patent landscape reports from IP consultants on pharmaceutical patents, 2000–2005.
[1] USPTO (2003). Patent 6,546,928.
